Strasbourg biotech appoints ceo

Mark Bloomfield aims to accelerate sales growth at Polyplus-transfection

Polyplus-transfection, a Strasbourg-based biotechnology firm developing solutions for scientists working in molecular and cell biology, has appointed Mark Bloomfield as chief executive.

Bloomfield replaces Frédéric Perraud who continues with Polyplus as chief operating officer and deputy ceo.

Polyplus is planning to accelerate revenue growth by launching reagents and solutions for cell transfection applications, by the commercialisation of ZNA technology through licensing agreements with Sigma-Aldrich and Metabion, as well as geographical sales channel expansion with partners in the US and major European and Asian markets.



Bloomfield has a background in chemistry and joins Polyplus-transfection after more than 15 years in sales and management positions with global companies in the biotechnology tools and analytical instruments markets.

‘I am very much looking forward to using my business experience with the company’s team of scientists, marketers and sales professionals to continue and accelerate its growth,’ said Bloomfield.

You may also like

Pharmaceutical

Polyplus introduces off-the-shelf plasmids for AAV2 production; plans to expand plasmid portfolio to support full range of AAV serotypes in 2024

Polyplus (part of Sartorius), a leading upstream solutions provider for advanced biologic and cell and gene therapy production from research to commercial grade, has launched pPLUS® AAV-RC2, a RepCap plasmid for adeno-associated virus vector 2 (AAV2) production
Research & Development

Polyplus-transfection raises €2.5m in funding

Will enable the firm to expand its therapeutic research activities
Packaging

How pharma packaging manufacturers role is evolving: the case of extractables testing

As the pharmaceutical industry continues to grow and evolve, extractables testing is a critical component of the pharmaceutical industry's efforts to prioritise quality and safety, ensuring one of the key functions pharma containers are designed for, says Anna Malori, Head of Product Management at Bormioli Pharma
Regulatory

Merck's Welireg approved for cancers associated with von Hippel-Lindau disease in China

The once-daily drug is the first HIF-2α to be approved in China, exhibiting a 49% objective response rate (ORR)
Manufacturing

Aurobindo Pharma signs $25m respiratory drug development and commercialisation deal with global pharma company

The companies will co-develop and commercialise respiratory therapeutics, diversifying Aurobindo's current portfolio
Packaging

Dual-chamber packaging systems as a simplification factor in the supply chain

Dual-chamber packaging solutions could represent a new frontier also to package parenteral drugs, simplifying the supply chain through reconstitution, potentially making logistics more flexible and efficient, says Cecilia Bassi, Product Manager at Bormioli Pharma
Regulatory

Pfizer gains European Commission approval for haemophilia A and B drug, Hympavzi

The subcutaneous therapeutic is the first and only anti-tissue factor pathway inhibitor approved for the treatment of haemophilia A or B, and is available in an auto-injector format
Subscribe now